Benzinga | Oct 14, 2020 08:31AM EDT

Ladenburg Thalmann Initiates Coverage On Cogent Biosciences with Buy Rating, Announces Price Target of $4

Ladenburg Thalmann analyst Matthew Kaplan initiates coverage on Cogent Biosciences (NASDAQ:COGT) with a Buy rating and announces Price Target of $4.